Aktis Oncology Inc. Common stock (AKTS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Aktis Oncology Inc. Common stock (AKTS) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.18 of bullish evidence against -0.36 bearish.

Aktis Oncology Inc. Common stock last closed at $16.64, -4.04% on the session.

Against the IVW growth benchmark the position is -4.00% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

22 graded predictions for AKTS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Aktis Oncology Inc. Common stock in the 20th percentile on return on equity, where 100 is best.

Aktis Oncology Inc. Common stock is classified under Health Care / Biotechnology, with a market capitalisation of $931.97M.

StockMap tracks Aktis Oncology Inc. Common stock as the 135th largest of the 388 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 303 Neutral, 69 Moderate Underperform and 16 Moderate Outperform.

On that composite Aktis Oncology Inc. Common stock ranks 314th of 388 in the group, against a group median of -0.08.